Shire to pay $56.5 million in final agreement with US government

25 September 2014

The US subsidiary of Ireland-headquartered Shire (LSE: SHP) will pay $56.5 million to resolve civil allegations that it violated the False Claims Act as a result of its marketing and promotion of several drugs, the US Justice Department announced yesterday.

Shire, which has recently agreed to a $54 billion takeover bid from the USA’s AbbVie (NYSE: ABBV), manufactures and sells pharmaceuticals, including Adderall XR (mixed amphetamine salts), Vyvanse (lisdexamfetamine) and Daytrana (methylphenidate transdermal system), which are approved for the treatment of attention deficit hyperactivity disorder (ADHD), and Pentasa /Lialda (mesalamine) which are approved for the treatment of mild to moderate active ulcerative colitis.

In addition, Shire will pay $2.9 million to resolve a previously disclosed civil complaint filed by the State of Louisiana alleging that the company's sales, marketing, and promotion of Adderall, Daytrana, Vyvanse and Intuniv (guanfacine) violated state law.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK